Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis
Company Announcement Phase III trials (ASCLEPIOS I and II) with the subcutaneous formulation of ofatumumab in Relapsing Multiple Sclerosis Studies expected to begin enrolling in September 2016 COPENHAGEN, Denmark, June 2, 2016 (GLOBE NEWSWIRE) -- Genmab A…